Imidazo[1,2‑a]pyridines as Privileged Scaffolds: Synthetic Advances, Biological Activities, and Translational Challenges
Giorgio Antoniolli, Rebeca Chaguri, Lorraine Alves Grabauskas, Denise Costa Arruda, Tiago Rodrigues · 2026
Read Imidazo[1,2‑a]pyridines as Privileged Scaffolds: Synthetic Advances, Biological Activities, and Translational Challenges by Giorgio Antoniolli, Rebeca Chaguri, Lorraine Alves Grabauskas, Denise Costa Arruda, Tiago Rodrigues (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13470714.txt.
Description
Antoniolli and colleagues reviewed in 2026 five years of work on imidazo[1,2-a]pyridines, a fused-ring chemical scaffold prized in drug design. A scaffold is the core frame of a molecule that chemists decorate to tune its action. This frame is stiff, easy to vary, and has a long record of yielding active compounds.
The review gathers new synthesis routes and the wide range of effects reported for these compounds. Variants have shown activity against cancer cells, bacteria, fungi, tuberculosis, parasites, and inflammation, among other targets. The authors map how small structural swaps change potency and describe designs that merge this core with other active frames. They also flag weak spots: many compounds lack animal testing and safety work, and most designs stick to familiar patterns.
Catalog record
| CREATOR | Giorgio Antoniolli, Rebeca Chaguri, Lorraine Alves Grabauskas, Denise Costa Arruda, Tiago Rodrigues |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 82 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |